DE-THE-LYCRA-COMPANY
23.7.2024 11:01:35 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and textile industry, has announced that its COOLMAX® EcoMade fiber made from 100% textile waste is a key ingredient in the Brazilian Volleyball team’s indoor and beach jerseys for the 2024 Summer Games in Paris. Body Work, a fitness brand from retailer Riachuelo, created the official uniforms unveiled in a stunning projection on the Christ the Redeemer statue overlooking Rio de Janeiro on June 27, Volleyball Day in Brazil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716778680/en/
Body Work, a fitness brand from Riachuelo, has revealed the official Brazilian Volleyball team shirts for the 2024 Summer Games. The fabric blends two technologies from The LYCRA Company: 92% COOLMAX® EcoMade fiber made from pre-consumer textile waste and 8% LYCRA® fiber to help keep athletes cool, dry, and moving freely. (Photo: Business Wire)
COOLMAX® EcoMade fiber transports moisture away from the body to the surface of the fabric, where it evaporates. This helps athletes stay cool, dry, and comfortable so they can focus on the game. It is one of many innovative branded fibers produced by The LYCRA Company designed to help optimize athletic performance. This technology converts pre-consumer textile waste scraps from garment manufacturers into fibers offering comparable performance to virgin polyester.
“We are thrilled that Brazil’s volleyball uniforms feature 92% COOLMAX® EcoMade fiber made from textile waste and 8% LYCRA® fiber, so we will be rooting for them in Paris,” said Nicolas Banyols, chief commercial officer - apparel, The LYCRA Company. “The benefits of activewear and sportswear with performance fibers are not limited to elite athletes anymore. Consumers of all abilities can now buy these innovative garments at retail, ensuring that everyone can experience the enhanced comfort and performance our fibers offer, in addition to options for durable and sustainable fibers for reduced environmental impact.”
LYCRA® brand fibers, now owned by The LYCRA Company, have been an integral part of the games since 1968, when the French alpine ski team dominated the medal count in Grenoble. The team's ski suits featured LYCRA® fiber, which provided a second-skin fit and greater freedom of movement. The long-standing history of performance and innovation in sports is a testament to the trust and reliability that the company’s fibers offer, instilling confidence in athletes and consumers alike.
“While the silver medal-winning 1984 Brazilian volleyball team uniform was the main inspiration for the design of this jersey, we wanted the fabric to be cutting-edge and future-focused,” said Camila de Paula Souza, Style Manager at Body Work | Riachuelo. “This fabric is designed to provide comfort and is made from textile waste—a win for athletes and a win for the planet.”
Consumers may purchase the official Brazilian Volleyball Team shirts at riachuleo.com. For more information on COOLMAX® EcoMade fiber benefits, visit coolmax.com.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
COOLMAX® and LYCRA® are trademarks of The LYCRA Company.
About Riachuelo
With over 75 years of history, Riachuelo operates with the purpose of connecting desires to achievements. By combining innovation, dynamism, and agility to deliver collections and products for all styles, the brand is a leading reference in the sector and is recognized as one of the largest fashion companies in Brazil. Riachuelo boasts more than 30 million cardholders and over 400 own stores across the country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716778680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom